ArticleFrontiers in oncology2024

Higher 3-year recurrence-free survival rate in patients with complete pathological remission following neoadjuvant chemotherapy plus immunotherapy for esophageal cancer: a two-center, propensity score matching study.

Hai Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.